Celldex has begun searching for a new chief financial officer after Senior Vice President and CFO Sam Martin informed the company of his plans to retire in 2027. Martin will remain as CFO through March of 2027 to support a smooth transition. He has served as CFO since 2017 and has been part of the Celldex finance team since April 2009. The immunology company is advancing its lead candidate barzolvolimab through Phase 3 trials in chronic spontaneous urticaria and other indications, with topline data expected later this year and a planned BLA submission in 2027. As of March 31, 2026, Celldex held $451.5 million in cash, cash equivalents, and marketable securities, and together with proceeds from an April public offering, it expects to fund planned operations through 2028.
Celldex Therapeutics IncCFO retirement plan announced, but transition is orderly and well-funded; no immediate financial impact.